Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EBITDA (2016 - 2025)

Historic EBITDA for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $29.4 million.

  • Tg Therapeutics' EBITDA rose 13616.7% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.8 million, marking a year-over-year increase of 2045227.72%. This contributed to the annual value of $41.9 million for FY2024, which is 10321.33% up from last year.
  • According to the latest figures from Q3 2025, Tg Therapeutics' EBITDA is $29.4 million, which was up 13616.7% from $34.8 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' EBITDA peaked at $114.8 million during Q3 2023, and registered a low of -$92.9 million during Q4 2021.
  • In the last 5 years, Tg Therapeutics' EBITDA had a median value of -$35.0 million in 2022 and averaged -$22.5 million.
  • Per our database at Business Quant, Tg Therapeutics' EBITDA skyrocketed by 42830.13% in 2023 and then plummeted by 8916.75% in 2024.
  • Over the past 5 years, Tg Therapeutics' EBITDA (Quarter) stood at -$92.9 million in 2021, then increased by 16.58% to -$77.5 million in 2022, then surged by 83.9% to -$12.5 million in 2023, then skyrocketed by 339.88% to $29.9 million in 2024, then decreased by 1.95% to $29.4 million in 2025.
  • Its EBITDA stands at $29.4 million for Q3 2025, versus $34.8 million for Q2 2025 and $8.6 million for Q1 2025.